Unicycive Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNCY research report →
Range $22 – $22
Price Chart
About the company
Unicycive Therapeutics, Inc. is a U. S.
- CEO
- Shalabh K. Gupta
- IPO
- 2021
- Employees
- 21
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on UNCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $97.77M
- P/E
- -2.10
- Fwd P/E
- 3.30
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 1.80
- EV/EBITDA
- -1.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.34%
- ROIC
- -65.18%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-572,000+0.0%
- Op Income
- $-29,517,000
- Net Income
- $-26,555,000+27.7%
- EPS
- $-1.67+70.4%
- OCF Growth
- -9.6%
- FCF Growth
- -9.4%
- 52W High
- $8.74
- 52W Low
- $3.33
- 50D MA
- $4.03
- 200D MA
- $5.88
- Beta
- 1.86
- RSI (14)
- 37
- Avg Volume
- 963.80K
No earnings-call transcripts are available for UNCY yet.
- Free Float
- 95.8%
- Shares Outstanding
- 29.18M
- Float Shares
- 27.95M
of shares held by institutions
90 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.41M | ▼ 6.36K |
| Nantahala Capital Management, LLC | 1.40M | ▲ 1 |
| Vanguard Capital Management LLC | 1.15M | ▲ 77.67K |
| Octagon Capital Advisors LP | 1.00M | 0 |
| Vanguard Group Inc | 788.59K | ▲ 129.71K |
| Geode Capital Management, LLC | 595.06K | ▲ 31.04K |
| State Street Corp | 479.60K | ▲ 29.43K |
| Logos Global Management LP | 473.56K | 0 |
| Diametric Capital, LP | 374.13K | ▲ 293.77K |
| J. Goldman & Co LP | 327.35K | ▲ 327.35K |
| Diadema Partners LP | 303.68K | ▲ 197.59K |
| Millennium Management LLC | 271.46K | ▼ 1.13M |
Held by 93 ETFs
Biggest fund positions in UNCY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Manning Meredith | other | 27,000 |
| Oct 28, 26 | Manning Meredith | other | 3,350 |
| Oct 1, 26 | Manning Meredith | other | 0 |
| May 14, 26 | Kenkare-Mitra Sara | other | 47,941 |
| May 14, 26 | Laumas Sandeep | other | 47,941 |
| May 14, 26 | Gupta Shalabh K. | other | 762,200 |
| May 14, 26 | Kenkare-Mitra Sara | other | 42,100 |
| May 14, 26 | Kenkare-Mitra Sara | other | 84,200 |
| May 14, 26 | Jermasek Douglas | other | 169,500 |
| May 14, 26 | Gupta Pramod | other | 169,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UNCY coverage
Recent articles, reports, and earnings notes.
No research on UNCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UNCY report →Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 16
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 4
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
businesswire.com · Nov 2
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
globenewswire.com · Nov 2
Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
globenewswire.com · Nov 2
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com · Nov 2
UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
newsfilecorp.com · Oct 31
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role
globenewswire.com · Oct 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.